sudden cardiac arrest ventricular arrhythmias
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must have an indication for an ICD according to ESC guidelines published in 2016: - Secondary prophylaxis for sudden cardiac death (SCD) and ventricular tachycardia (VT), - Primary prophylaxis for SCD and VT - Left ventricular ejection fraction (LVEF)
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Age 120 ms - Contra-indications for ICD-implantation - Permanent atrial fibrillation - Atrioventricular block, 2nd and 3rd degree
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short-term variability of repolarization (STV) of 30 consecutive beats is measured from different recording sites (ECG, RV EGM, LV EGM, unipolar & bipolar signals). STV is claculated with the formula *|D(n+1)-Dn |/30×*2, where D represents the repolarization duration and n the number of complexes, in this case 30 complexes. The repolarization duration is defined and measured differently per recording site. All intracardiac and ECG leads can be recorded simultaneously. - STV-QT: QT-interval is defined as the interval from the beginning of the Q-wave until the end of the T-wave. - STV-ARI: repolarization duration is defined as the interval from the minimal dV/dt of the QRS complex to the maximum or minimum dV/dt of the T wave, depending on the morphology of the T-wave. | — |
Secondary
| Measure | Time frame |
|---|---|
| -- Age at implantation; - Sex; - Left ventricular ejection fraction (LVEF) measured by MRI, nuclear imaging or echocardiography; - NYHA class; - Underlying cardiac disease (ischemic cardiomyopathy, dilated cardiomyopathy, other); - Cardiovascular risk factors( smoking, hypertension, diabetes mellitus, peripheral artery disease, COPD) - Relevant comorbidities (COPD, chronic kidney disease, malignancy) - Medications (beta blockers, ACE-inhibitors/AT2-antagonists, aldosterone antagonists, diuretics, calcium blockers, digoxin, class I or III anti-arrhythmic drugs) - ECG parameters (RR-interval, PQ-interval, QRS-duration, QRS-morphology, RV-pacing: yes/no) | — |
Countries
Netherlands
Outcome results
None listed